Home
Login
Expand All
|
Collapse All
Guidelines for Managing Sexually Transmitted Infections - WA
Table of Contents
Foreword
Publication Details
List of Contributors
List of Abbreviations
Medicines in Pregnancy
Contacts for Specialist Advice on STIs and HIV
Contacts for Patients - Where to Go
Introduction
1. Principles of STI/HIV Management
1.1. General Principles
1.1.1. Effective Clinical Management of Patients Who May Have an STI or HIV
1.1.2. The Clinic Environment
1.1.3. Respect for Patients' Special Needs
1.1.3.1. Opportunistic Screening
1.1.4. History
1.1.5. Suggested Range of Tests
1.1.6. Principles for Community Screening*
1.1.7. Prevention and Education for STIs/HIV
1.1.8. Child Sexual Abuse and STIs
1.1.9. Management of a Child with an STI
1.1.10. STI/HIV Notifications
1.1.11. STI/HIV Counselling
1.1.12. Follow Up Screening
1.2. History and Examination
1.2.1. Relevant History
1.2.2. Sexual History
1.2.3. Drug History and Other Factors
1.2.4. Consent to Physical Examination
1.2.5. The Physical Examination
1.2.6. STI Clinical Management and Sexual Contact Interview and Tracing Forms
1.3. Patient Presentation and Specimen Collection
1.3.1. Essential Tests
1.3.2. Specimen Collection and Handling Checklist
1.3.2.1. Vaginal pH Testing
1.3.3. Essential Communication
1.3.4. Nucleic Acid Amplification Tests
1.3.5. Sample Test Pack for Diagnostic Testing
1.3.6. Sample Protocol for Chlamydia and Gonorrhoea Diagnosis
1.3.7. Specimen Collection: Men
1.3.8. Specimen Collection in Women Who are Examined
1.4. Screening of Asymptomatic Men and Women
1.4.1. Screening of Asymptomatic Men and Women
1.4.2. Asymptomatic Males
1.4.3. Asymptomatic Females
1.4.4. All Cases
1.5. Sexually Transmitted Infection Syndromes
1.5.1. Sexually Transmitted Infection Syndromes
1.5.2. Vaginal Discharge
1.5.3. Urethral Discharge/Dysuria in Men
1.5.4. Genital Ulceration
1.5.5. Lower Abdominal Pain Syndrome
1.5.6. Acute Proctitis
1.6. Contact Tracing (Managing Sex Partners)
1.6.1. Contact Tracing: Definitions
1.6.2. Principles of Contact Tracing
1.6.3. Information for Contact Tracing
1.6.4. Choosing a Method for Advising Contacts
1.6.5. Empirical Treatment
1.6.6. Follow Up
1.6.7. Urgency of Contact Tracing
1.6.8. Uncooperative Patients
1.6.9. Sample STI and HIV Contact Tracing Forms
1.7. STI Screening Recommendations for High Risk Populations
1.7.1. Current Sex Workers
1.7.2. Asymptomatic Young People (Under 25 Years)*
1.7.3. Asymptomatic Sexually Active People Who Have Injected Drugs in the Last 12 Months*
1.7.4. Men Who Have Sex with Men*
2. Notifiable Infections
2.1. Chancroid
2.1.1. Organism
2.1.2. Clinical Presentation
2.1.3. Investigations
2.1.4. Treatment
2.1.5. Management of Partners
2.1.6. Follow Up
2.1.7. Public Health Issues
2.2. Chlamydia
2.2.1. Organism
2.2.2. Clinical Presentation
2.2.3. Investigations
2.2.4. Treatment
2.2.5. Education, Counselling and Prevention
2.2.6. Management of Partners
2.2.7. Follow Up
2.2.8. Public Health Issues
2.3. Donovanosis (Granuloma Inguinale)
2.3.1. Organism
2.3.2. Clinical Presentation
2.3.3. Investigations
2.3.4. Treatment
2.3.5. Education, Counselling and Prevention
2.3.6. Management of Partners
2.3.7. Follow Up
2.3.8. Public Health Issues
2.4. Gonorrhoea
2.4.1. Organism
2.4.2. Clinical Presentation
2.4.3. Investigations
2.4.4. Treatment
2.4.5. Education, Counselling and Prevention
2.4.6. Management of Partners
2.4.7. Follow Up
2.4.8. Public Health Issues
2.5. Human Immunodeficiency Infection (HIV) and Acquired Immunodeficiency Syndrome (AIDS)
2.5.1. Organism
2.5.2. Clinical Presentation
2.5.3. Investigations
2.5.4. Treatment
2.5.5. Education, Counselling and Prevention
2.5.6. Management of Partners
2.5.7. Follow Up
2.5.8. Public Health Issues
2.6. Lymphogranuloma Venereum
2.6.1. Organism
2.6.2. Clinical Presentation
2.6.3. Investigations
2.6.4. Treatment
2.6.5. Management of Partners
2.6.6. Follow Up
2.6.7. Public Health Issues
2.7. Syphilis
2.7.1. Organism
2.7.2. Clinical Presentation
2.7.3. Investigations
2.7.4. Treatment
2.7.5. Education, Counselling and Prevention
2.7.6. Management of Partners
2.7.7. Follow Up
2.7.8. Syphilis in HIV Infection
2.7.9. Syphilis During Pregnancy
2.7.10. Congenital Syphilis
2.7.11. Public Health Issues
2.8. Viral Hepatitis
2.8.1. Overview
2.8.2. Hepatitis A
2.8.3. Hepatitis B
2.8.4. Hepatitis C
3. Non-Notifiable Infections
3.1. Bacterial Vaginosis
3.1.1. Organism
3.1.2. Clinical Presentation
3.1.3. Investigations
3.1.4. Treatment
3.1.5. Management of Partners
3.1.6. Follow Up
3.1.7. Public Health Issues
3.2. Candidiasis
3.2.1. Organism
3.2.2. Clinical Presentation
3.2.3. Investigations
3.2.4. Treatment
3.2.5. Management of Partners
3.2.6. Follow Up
3.2.7. Public Health Issues
3.3. Cervicitis
3.3.1. Definition
3.3.2. Clinical Presentation
3.3.3. Investigations
3.3.4. Treatment
3.3.5. Management of Partners
3.3.6. Follow Up
3.3.7. Public Health Issues
3.4. Cytological Abnormalities
3.5. Epididymo-orchitis
3.5.1. Clinical Presentation
3.5.2. Investigations
3.5.3. Treatment
3.5.4. Management of Partners
3.5.5. Follow Up
3.5.6. Public Health Issues
3.6. Genital Herpes
3.6.1. Organism
3.6.2. Clinical Presentation
3.6.3. Investigations
3.6.4. Treatment
3.6.5. Management of Partners
3.6.6. Follow Up
3.6.7. Public Health Issues
3.7. Genital Warts/HPV
3.7.1. Organism
3.7.2. Clinical Presentation
3.7.3. Investigations
3.7.4. Treatment
3.7.5. Management of Partners
3.7.6. Follow Up
3.7.7. Public Health Issues
3.8. Molluscum Contagiosum
3.8.1. Organism
3.8.2. Clinical Presentation
3.8.3. Investigations
3.8.4. Treatment
3.8.5. Management of Partners
3.8.6. Follow Up
3.8.7. Public Health Issues
3.9. Non-Specific Urethritis (Persistent or Recurrent NSU)
3.9.1. Overview
3.9.2. Clinical Presentation
3.9.3. Investigations
3.9.4. Treatment
3.9.5. Management of Partners
3.9.6. Follow Up
3.9.7. Public Health Issues
3.10. Pelvic Inflammatory Disease (PID)
3.10.1. Definition
3.10.2. Organism
3.10.3. Clinical Presentation
3.10.4. Investigations
3.10.5. Treatment
3.10.6. Education, Counselling and Prevention
3.10.7. Management of Partners
3.10.8. Follow Up
3.10.9. Public Health Issues
3.11. Prostatitis
3.11.1. Clinical Presentation
3.11.2. Treatment
3.12. Pubic Lice
3.12.1. Organism
3.12.2. Clinical Presentation
3.12.3. Investigations
3.12.4. Treatment
3.12.5. Management of Partners
3.12.6. Follow Up
3.12.7. Public Health Issues
3.13. Scabies
3.13.1. Organism
3.13.2. Clinical Presentation
3.13.3. Investigations
3.13.4. Treatment
3.13.5. Management of Partners
3.13.6. Follow Up
3.13.7. Public Health Issues
3.14. Trichomoniasis
3.14.1. Organism
3.14.2. Clinical Presentation
3.14.3. Investigations
3.14.4. Treatment
3.14.5. Management of Partners
3.14.6. Follow Up
3.14.7. Public Health Issues
4. Appendices
4.1. Sample Letters
4.1.1. Sample Letter Re: Contact Tracing
4.1.2. Sample Letter Re: Empirical Treatment
4.2. Tables
4.2.1. Risk of Transmission Following HIV Exposure
4.2.2. Health Advice and Follow-up
4.3. Australian National Notifiable Diseases Case Definitions*
4.3.1. Acquired Immunodeficiency Syndrome (AIDS)
4.3.2. Hepatitis B (Newly Acquired)
4.3.3. Hepatitis B (Unspecified)
4.3.4. Hepatitis C (Newly Acquired)
4.3.5. Hepatitis C (Unspecified)
4.3.6. Human Immunodeficiency Virus (HIV) - Child < 18 Months at Time of Blood Sample Collection
4.3.7. Human Immunodeficiency Virus (HIV) (Newly Acquired)
4.3.8. Human Immunodeficiency Virus (HIV) (Unspecified)
4.3.9. Chancroid (Soft Sore)
4.3.10. Chlamydial Infection
4.3.11. Donovanosis
4.3.12. Gonococcal Infection
4.3.13. Syphilis – Less than Two Years Duration (Infectious – Primary, Secondary and Early Latent)
4.3.14. Syphilis – More than Two Years Duration or Unspecified Duration
4.3.15. Syphilis - Congenital
4.4. WA Endemic Regions STI/HIV Control Supplement
4.5. 3 Minute Quick Start Video
4.6. Quick Guides for STIs
4.7. Toolbox
Bibliography
Glossary
Last Updated - 08th March 2012
Site feedback
